Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rimoldi

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
The Journal of Experimental Medicine|September 22, 1998
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growthM Hahne, T Kataoka, M Schröter, et al.
Nature|July 10, 1997
Inhibition of death receptor signals by cellular FLIPM Irmler, M Thome, M Hahne, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 20, 2000
Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanomaD Rimoldi, V Rubio-Godoy, V Dutoit, et al.
Cancer Letters|February 27, 2007
Potential target antigens for immunotherapy in human pancreatic cancerF H Schmitz-Winnenthal, L V Galindo-Escobedo, D Rimoldi, et al.
Cancer Research|August 2, 2001
Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activityV Dutoit, V Rubio-Godoy, P Y Dietrich, et al.
Biomedical Optics Express|May 28, 2016
Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurementsH A R Homulle, F Powolny, P L Stegehuis, et al.
International Journal of Cancer|June 11, 1996
Infrequent expression of the MAGE gene family in uveal melanomasK A Mulcahy, D Rimoldi, F Brasseur, et al.
Nuklearmedizin. Nuclear Medicine|December 18, 2007
Sentinel lymph node involvement and a high Breslow index are independent factors of risk for early relapse of melanomaJ-P Willi, M Matter, F Buchegger, et al.
Oncoimmunology|November 18, 2016
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses with multiple specificities including a novel DR7-restricted epitopeP Baumgaertner, C Costa Nunes, A Cachot, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
The Journal of Experimental Medicine|September 22, 1998
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growthM Hahne, T Kataoka, M Schröter, et al.
Nature|July 10, 1997
Inhibition of death receptor signals by cellular FLIPM Irmler, M Thome, M Hahne, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 20, 2000
Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanomaD Rimoldi, V Rubio-Godoy, V Dutoit, et al.
Cancer Letters|February 27, 2007
Potential target antigens for immunotherapy in human pancreatic cancerF H Schmitz-Winnenthal, L V Galindo-Escobedo, D Rimoldi, et al.
Cancer Research|August 2, 2001
Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activityV Dutoit, V Rubio-Godoy, P Y Dietrich, et al.
Biomedical Optics Express|May 28, 2016
Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurementsH A R Homulle, F Powolny, P L Stegehuis, et al.
International Journal of Cancer|June 11, 1996
Infrequent expression of the MAGE gene family in uveal melanomasK A Mulcahy, D Rimoldi, F Brasseur, et al.
Nuklearmedizin. Nuclear Medicine|December 18, 2007
Sentinel lymph node involvement and a high Breslow index are independent factors of risk for early relapse of melanomaJ-P Willi, M Matter, F Buchegger, et al.
Oncoimmunology|November 18, 2016
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses with multiple specificities including a novel DR7-restricted epitopeP Baumgaertner, C Costa Nunes, A Cachot, et al.
Pageof 7